Spiking Expression of μ-Crystallin mRNA during Treatment with Methimazole in Patients with Graves’ Hyperthyroidism

Abstract

μ-Crystallin is an NADPH-dependent cytosolic T3-binding protein. A knockout study in mice showed that μ-crystallin has a physiological function as a reservoir of T3 in the cytoplasm in vivo. Patients with nonsyndromic deafness were reported to have point mutations in the μ-crystallin gene. The expression of μ-crystallin is regulated by multiple factors. The present study was performed to determine whether thyroid function is related to the expression of μ-crystallin mRNA in peripheral mononuclear cells. We examined 23 normal healthy male and female subjects and 15 patients with Graves’ disease. μ-Crystallin protein expression was determined immunohistochemically in peripheral mononuclear cells. The expression of μ-crystallin mRNA was assessed by reverse transcription of total RNA from peripheral mononuclear cells followed by quantitative PCR. μ-Crystallin protein was detected in peripheral mononuclear cells. The mRNA expression was negatively correlated with age in normal female subjects. The values in female subjects were significantly higher than those in males. The values were positively correlated with serum TSH concentration. The values of the thyrotoxic patients with Graves’ disease were lower than those in healthy subjects. A transient increase in μ-crystallin expression was observed within 14–42 days after the initial treatment with antithyroid medication. Thyroid hormone inversely relates to the expression of μ-crystallin mRNA in euthyroid mononuclear cells. Abrupt suppression of thyroid function leads to overexpression of μ-crystallin mRNA in thyrotoxic mononuclear cells. Thyroid hormone-regulated μ-crystallin expression may control thyroid hormone action via the intracytoplasmic T₃ capacity.

CRYM - thyroid hormone - thyroid hormone binding protein - μ-crystallin - hyperthyroidism

References

• 1 Larsen PR, Davies TF, Schlumberger M-J, Hay ID. Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (eds). Williams textbook of endocrinology 11th ed. Philadelphia: Saunders 2008: 299-332
• 2 Visser WE, Friesema EC, Jansen J, Visser TJ. Thyroid hormone transport in and out of cells.  Trends Endocrinol Metab. 2008;  19 50-56
• 3 Suzuki S, Mori J-I, Kobayashi M, Inagaki T, Komatsu A, Yamashita K, Takeda T, Miyamoto T, Ichikawa K, Hashizume K. Presence of functional domains in NADPH-dependent cytosolic 3,5,3′-triiodo-l-thyronine (T3)-binding protein (p38CTBP) molecule: analysis with deletion mutants.  Horm Metab Res. 2003;  35 577-582
• 4 Mori J-I, Suzuki S, Kobayashi M, Inagaki T, Komatsu A, Takeda T, Miyamoto T, Ichikawa K, Hashizume K. Nicotinamide adenine dinucleotide phosphate-dependent cytosolic T3 binding protein as a regulator for T3-mediated transactivation.  Endocrinology. 2002;  143 1538-1544
• 5 Abe S, Katagiri T, Saito-Hisaminato A, Usami S, Inoue Y, Tsunoda T, Nakamura Y. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues.  Am J Hum Genet. 2003;  72 73-82
• 6 Oshima A, Suzuki S, Takumi Y, Hashizume K, Abe S, Usami S. CRYM mutations cause deafness through thyroid hormone binding properties in the fibrocytes of the cochlea.  J Med Genet. 2006;  43 e25
• 7 Suzuki S, Mori J-I, Hashizume K. μ-Crystallin, a NADPH-dependent T3-binding protein in cytosol.  Trends Endocrinol Metab. 2007;  18 286-289
• 8 Nishii Y, Hashizume K, Ichikawa K, Takeda T, Kobayashi M, Nagasawa T, Katai M, Kobayashi H, Sakurai A. Induction of cytosolic triiodothyronine (T3) binding protein (CTBP) by T3 in primary cultured rat hepatocytes.  Endocr J. 1993;  40 399-404
• 9 Yan L, Li F, Ding-Geng C, Samir SD. Identification of novel retinal target genes of thyroid hormone in the human WER1 cells by expression microarray analysis.  Vision Res. 2007;  47 2314-2326
• 10 Komatsu A, Suzuki S, Inagaki T, Yamashita K, Hashizume K. A kindred with cockayne syndrome caused by multiple splicing variants of the CSA gene.  Am J Med Genet. 2004;  128A 67-71
• 11 Suzuki S, Mori J, Kobayashi M, Inagaki T, Inaba H, Komatsu A, Yamashita K, Takeda T, Miyamoto T, Ichikawa K, Hashizume K. Cell-specific expression of NADPH-dependent cytosolic 3,5,3′-triiodo-l-thyronine-binding protein (p38CTBP).  Eur J Endocrinol. 2003;  148 259-268
• 12 Usami S, Takumi Y, Suzuki N, Oguchi T, Oshima A, Suzuki H, Kitoh R, Abe S, Sasaki A, Matsubara A. The localization of proteins encoded by CRYM, KIAA1199, UBA52, COL9A3, and COL9A1, genes highly expressed in the cochlea.  Neuroscience. 2008;  154 22-28
• 13 Arpin C, Pihlgren M, Fraichard A, Aubert D, Samarut J, Chassande O, Marvel J. Effects of T3Rα1 and T3Rα2 gene deletion on T and B lymphocyte development.  J Immunol. 2000;  164 152-160
• 14 Kendrick TS, Payne CJ, Epis MR, Schneider JR, Leedman PJ, Klinken SP, Ingley E. Erythroid defects in TRα –/– mice.  Blood. 2008;  111 3245-3248
• 15 Ko C, Grieshaber NA, Ji I, Ji TH. Follicle-stimulating hormone suppresses cytosolic 3,5,3′-triiodothyronine-binding protein messenger ribonucleic acid expression in rat granulose cells.  Endocrinology. 2003;  144 2360-2367
• 16 Bartalena L. Recent achievements in studies on thyroid hormone-binding proteins.  Endocr Rev. 1990;  11 47-64
• 17 Liu C, Papewalis C, Domberg J, Scherbaum WA, Schott M. Chemokines and autoimmune thyroid diseases.  Horm Metab Res. 2008;  40 361-368
• 18 Suzuki S, Suzuki N, Mori J-I, Oshima A, Usami S, Hashizume K. Crystallin as an intracellular 3,5,3′-triiodothyronine holder in vivo.  Mol Endocrinol. 2007;  21 885-894

Correspondence